These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 9824138)

  • 21. [Preliminary clinic observation on the inhibition of HBV by receptor-targeted drug L-HSA-AraAMP].
    Wang H; Zhang L; Wang X
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1998 Mar; 12(1):12-4. PubMed ID: 12515162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B.
    Chan HL; Wong VW; Chim AM; Choi PC; Chan HY; Hui AY; Wong GL; Sung JJ
    Antivir Ther; 2007; 12(5):815-23. PubMed ID: 17713165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B.
    Koffi J; Egounlety R; Pradat P; Lebosse F; Si-Ahmed SN; Lussier V; Chevallier P; Bailly F; Zoulim F
    Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):146-54. PubMed ID: 24025974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changing landscape of antiviral resistance management in chronic hepatitis B.
    Nguyen T; Locarnini S; Desmond P
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1314-7. PubMed ID: 18853991
    [No Abstract]   [Full Text] [Related]  

  • 25. [Bringing the antiviral therapy home for chronic hepatitis B patients: host immunity influences the efficacy and disease prognosis].
    Wang FS; Zhang JY
    Zhonghua Gan Zang Bing Za Zhi; 2009 Mar; 17(3):164-6. PubMed ID: 19554778
    [No Abstract]   [Full Text] [Related]  

  • 26. Adenine arabinoside therapy in HBsAg-positive chronic liver disease: a controlled study.
    Bassendine MF; Chadwick RG; Salmeron J; Shipton U; Thomas HC; Sherlock S
    Gastroenterology; 1981 May; 80(5 pt 1):1016-22. PubMed ID: 7009310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is ribavirin treatment really effective for chronic hepatitis B?
    Kakumu S
    J Gastroenterol; 2000; 35(5):404-6. PubMed ID: 10832679
    [No Abstract]   [Full Text] [Related]  

  • 28. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of adenine arabinoside on serum and intrahepatic replicative forms of duck hepatitis B virus in chronic infection.
    Hirota K; Sherker AH; Omata M; Yokosuka O; Okuda K
    Hepatology; 1987; 7(1):24-8. PubMed ID: 3804202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
    Takkenberg B; Terpstra V; Zaaijer H; Weegink C; Dijkgraaf M; Jansen P; Beld M; Reesink H
    J Gastroenterol Hepatol; 2011 Oct; 26(10):1527-35. PubMed ID: 21557773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful treatment of HBs and HBeAg positive chronic liver disease: prolonged inhibition of viral replication by highly soluble adenine arabinoside 5'-monophosphate (ARA-AMP).
    Weller IV; Bassendine MF; Craxi A; Fowler MJ; Monjardino J; Thomas HC; Sherlock S
    Gut; 1982 Sep; 23(9):717-23. PubMed ID: 6179819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers.
    Kohmoto M; Enomoto M; Tamori A; Habu D; Takeda T; Kawada N; Sakaguchi H; Seki S; Shiomi S; Nishiguchi S
    J Med Virol; 2005 Feb; 75(2):235-9. PubMed ID: 15602726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients.
    Chan HL; Wong GL; Chim AM; Chan HY; Chu SH; Wong VW
    Antivir Ther; 2011; 16(8):1249-57. PubMed ID: 22155906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of hepatitis B virus replication by adenine arabinoside monophosphate coupled to lactosaminated albumin. Efficacy and minimal active dose.
    Torrani Cerenzia MR; Fiume L; Busi C; Mattioli A; Di Stefano G; Gervasi GB; Brunetto MR; Piantino P; Verme G; Bonino F
    J Hepatol; 1994 Feb; 20(2):307-9. PubMed ID: 7516363
    [No Abstract]   [Full Text] [Related]  

  • 35. Early hepatitis B viral DNA clearance predicts treatment response at week 96.
    Fu XY; Tan DM; Liu CM; Gu B; Hu LH; Peng ZT; Chen B; Xie YL; Gong HY; Hu XX; Yao LH; Xu XP; Fu ZY; He LQ; Li SH; Long YZ; Li DH; Gu JL; Peng SF
    World J Gastroenterol; 2017 Apr; 23(16):2978-2986. PubMed ID: 28522916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.
    Viganò M; Mangia G; Lampertico P
    Expert Opin Biol Ther; 2014 Jul; 14(7):1019-31. PubMed ID: 24909454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recurrence of hepatitis B in liver transplants treated with antiviral therapy.
    Marzano A; Debernardi-Venon W; Smedile A; Brunetto MR; Torrani Cerenzia MR; Actis GC; Zamboni F; Ghisetti V; Piantino P; David E; Salizzoni M; Rizzetto M
    Ital J Gastroenterol Hepatol; 1998 Feb; 30(1):77-81. PubMed ID: 9615271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine.
    Zhang Y; Lian JQ; Li Y; Wang JP; Huang CX; Bai XF; Wang JP
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):814-9. PubMed ID: 23406845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B.
    Manesis EK; Papatheodoridis GV; Tiniakos DG; Hadziyannis ES; Agelopoulou OP; Syminelaki T; Papaioannou C; Nastos T; Karayiannis P
    J Hepatol; 2011 Jul; 55(1):61-8. PubMed ID: 21145875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Management of HBeAg negative chronic hepatitis B].
    Jia JD
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):539. PubMed ID: 16042896
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.